Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1590/s0004-282x2008000600020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Heterogeneity Assessment and Protein Pathway Prediction via Spatial Lipidomic and Proteomic Correlation: Advancing Dry Proteomics concept for Human Glioblastoma Prognosis.
Mol Cell Proteomics
December 2024
Univ.Lille, Inserm, CHU Lille, U1192 - Proteomics Inflammatory Response Mass Spectrometry- PRISM, F-59000 Lille, France; Institut Universitaire de France, 75000 Paris. Electronic address:
Prediction of proteins and associated biological pathways from lipid analyses via MALDI MSI is a pressing challenge. We introduced "dry proteomics," using MALDI MSI to validate spatial localization of identified optimal clusters in lipid imaging. Consistent cluster appearance across omics images suggests association with specific lipid and protein in distinct biological pathways, forming the basis of dry proteomics.
View Article and Find Full Text PDFA new nano approach to prevent tumor growth in the local treatment of glioblastoma: Temozolomide and rutin-loaded hybrid layered composite nanofiber.
Asian J Pharm Sci
December 2024
Department of Medical Biology, Faculty of Medicine, Bursa Uludag University, Bursa, Turkey.
Total resection of glioblastoma (GB) tumors is nearly impossible, and systemic administration of temozolomide (TMZ) is often inadequate. This study presents a hybrid layered composite nanofiber mesh (LHN) designed for localized treatment in GB tumor bed. The LHN, consisting of polyvinyl alcohol and core-shell polylactic acid layers, was loaded with TMZ and rutin.
View Article and Find Full Text PDFFreiburg Neuropathology Case Conference : Posterior fossa tumour 15 years after microsurgical resection of a cerebellar pilocytic astrocytoma.
Clin Neuroradiol
December 2024
Department of Neuroradiology, Medical Center, University of Freiburg, Breisacherstraße 64, 79106, Freiburg, Germany.
Preclinical assessment of MAGMAS inhibitor as a potential therapy for pediatric medulloblastoma.
PLoS One
October 2024
Department of Neurology, School of Medicine, University of Irvine, Irvine, CA, United States of America.
Article Synopsis
- Medulloblastoma, the most common malignant brain tumor in children, has distinct subgroups, including WNT-driven and SHH-driven types, and this study focuses on the small molecule MAGMAS inhibitor, BT9, previously shown to impact adult glioblastoma.
- The research involved treating human medulloblastoma cell lines (DAOY and D425) with BT9 and assessing effects on cell proliferation, death, migration, invasion, and metabolic activity through various assays.
- While BT9 significantly reduced cell proliferation and increased death in vitro, it did not improve survival in an in vivo mouse model, indicating potential antitumor effects but limited efficacy in living organisms.
Proton beam therapy in a patient with secondary glioblastoma (32 years after postoperative irradiation of medulloblastoma): case report and literature review.
Radiat Oncol
October 2024
Department of Pediatric Radiation Therapy Center/Pediatric Proton Beam Therapy Center, Hebei Yizhou Cancer Hospital, Zhuozhou, 072750, China.
Article Synopsis
- This report highlights the case of a male patient who developed a second glioblastoma 32 years after being treated for medulloblastoma, emphasizing the treatment process and relevant literature.
- The patient underwent successful surgery and was treated with proton beam therapy and Temozolomide, resulting in a complete response after his radiation-induced glioblastoma was diagnosed.
- The discussion includes the importance of molecular profiling in managing second primary tumors like RIGB and underscores the advantages of proton beam therapy for protecting healthy tissue during high-dose treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!